INT205652

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.74
Pain Relevance 0.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

UOX (Homo sapiens)
Pain Link Frequency Relevance Heat
Arthritis 4 61.36 Quite High
Bioavailability 2 53.44 Quite High
adenocard 4 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
pruritus 2 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Crystal Associated Disease 44 97.92 Very High Very High Very High
Tumor Lysis Syndrome 62 97.80 Very High Very High Very High
Hypersensitivity 38 89.88 High High
Malignant Neoplastic Disease 4 87.84 High High
Arthritis 6 81.96 Quite High
Hyperuricemia 62 77.12 Quite High
Leukopenia 2 72.08 Quite High
Urolithiasis 4 62.00 Quite High
Glucose Metabolism Disorders 2 55.80 Quite High
Death 2 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Already before 2002, when Food and Drugs Administration (FDA) of US has approved the use of urate oxidase for the management of paediatric patients at risk for TLS (Tumor Lysis Syndrome) 26, urate oxidase was used for this purpose with good efficacy. 13,14,27-30 Currently US FDA does not approve its use in adult, instead EU FDA has approved it in children and adult. 19
Localization (use) of urate oxidase associated with tumor lysis syndrome
1) Confidence 0.50 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.76 Pain Relevance 0
A trial, in which PEG-uricase was administered subcutaneously in patients with severe, refractory gout at doses between 4-24 mg in a single dose, has showed a reduction of uric acid pool until 21 days. 16
Localization (administered) of PEG-uricase associated with crystal associated disease
2) Confidence 0.43 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.98 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox